Activity of epirubicin and dibromodulcitol in advanced breast cancer. Results of the South-East European oncology group study

S. Eckhardt, E. Juhos, I. Hindy, S. Jelic, I. Koza, G. Laszlo, Z. Mechl, T. Nagykalnay, M. Pawlicki, Z. Schoket, P. Siedlecki, L. Svancarova, J. Szántó, L. Vuletic, J. Zborzil

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

The therapeutic efficacy of the combination of epirubicin + dibromodulcitol was evaluated in 108 previously treated or untreated patients with advanced breast cancer. The overall response rate was 39.8%, complete remission 3.7% (mean duration 6.3 months) and partial remission 36.1% (mean duration 3.5 months). The response was rated in function of age, menopausal status, performance status and previous therapy. Toxicity (in case of 115 patients) was evaluated according to the WHO recommendation. The similar therapeutic effectiveness and less toxicity of the above drug combination compared to ADM + DBD regimen are demonstrated.

Original languageEnglish
Pages (from-to)409-412
Number of pages4
JournalOncology
Volume45
Issue number6
Publication statusPublished - 1988

Fingerprint

Mitolactol
Epirubicin
Breast Neoplasms
Drug Combinations
Therapeutics

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Eckhardt, S., Juhos, E., Hindy, I., Jelic, S., Koza, I., Laszlo, G., ... Zborzil, J. (1988). Activity of epirubicin and dibromodulcitol in advanced breast cancer. Results of the South-East European oncology group study. Oncology, 45(6), 409-412.

Activity of epirubicin and dibromodulcitol in advanced breast cancer. Results of the South-East European oncology group study. / Eckhardt, S.; Juhos, E.; Hindy, I.; Jelic, S.; Koza, I.; Laszlo, G.; Mechl, Z.; Nagykalnay, T.; Pawlicki, M.; Schoket, Z.; Siedlecki, P.; Svancarova, L.; Szántó, J.; Vuletic, L.; Zborzil, J.

In: Oncology, Vol. 45, No. 6, 1988, p. 409-412.

Research output: Contribution to journalArticle

Eckhardt, S, Juhos, E, Hindy, I, Jelic, S, Koza, I, Laszlo, G, Mechl, Z, Nagykalnay, T, Pawlicki, M, Schoket, Z, Siedlecki, P, Svancarova, L, Szántó, J, Vuletic, L & Zborzil, J 1988, 'Activity of epirubicin and dibromodulcitol in advanced breast cancer. Results of the South-East European oncology group study', Oncology, vol. 45, no. 6, pp. 409-412.
Eckhardt, S. ; Juhos, E. ; Hindy, I. ; Jelic, S. ; Koza, I. ; Laszlo, G. ; Mechl, Z. ; Nagykalnay, T. ; Pawlicki, M. ; Schoket, Z. ; Siedlecki, P. ; Svancarova, L. ; Szántó, J. ; Vuletic, L. ; Zborzil, J. / Activity of epirubicin and dibromodulcitol in advanced breast cancer. Results of the South-East European oncology group study. In: Oncology. 1988 ; Vol. 45, No. 6. pp. 409-412.
@article{65a2d03bcf9b4c11b27f0d390fa9a89c,
title = "Activity of epirubicin and dibromodulcitol in advanced breast cancer. Results of the South-East European oncology group study",
abstract = "The therapeutic efficacy of the combination of epirubicin + dibromodulcitol was evaluated in 108 previously treated or untreated patients with advanced breast cancer. The overall response rate was 39.8{\%}, complete remission 3.7{\%} (mean duration 6.3 months) and partial remission 36.1{\%} (mean duration 3.5 months). The response was rated in function of age, menopausal status, performance status and previous therapy. Toxicity (in case of 115 patients) was evaluated according to the WHO recommendation. The similar therapeutic effectiveness and less toxicity of the above drug combination compared to ADM + DBD regimen are demonstrated.",
author = "S. Eckhardt and E. Juhos and I. Hindy and S. Jelic and I. Koza and G. Laszlo and Z. Mechl and T. Nagykalnay and M. Pawlicki and Z. Schoket and P. Siedlecki and L. Svancarova and J. Sz{\'a}nt{\'o} and L. Vuletic and J. Zborzil",
year = "1988",
language = "English",
volume = "45",
pages = "409--412",
journal = "Oncology",
issn = "0030-2414",
publisher = "S. Karger AG",
number = "6",

}

TY - JOUR

T1 - Activity of epirubicin and dibromodulcitol in advanced breast cancer. Results of the South-East European oncology group study

AU - Eckhardt, S.

AU - Juhos, E.

AU - Hindy, I.

AU - Jelic, S.

AU - Koza, I.

AU - Laszlo, G.

AU - Mechl, Z.

AU - Nagykalnay, T.

AU - Pawlicki, M.

AU - Schoket, Z.

AU - Siedlecki, P.

AU - Svancarova, L.

AU - Szántó, J.

AU - Vuletic, L.

AU - Zborzil, J.

PY - 1988

Y1 - 1988

N2 - The therapeutic efficacy of the combination of epirubicin + dibromodulcitol was evaluated in 108 previously treated or untreated patients with advanced breast cancer. The overall response rate was 39.8%, complete remission 3.7% (mean duration 6.3 months) and partial remission 36.1% (mean duration 3.5 months). The response was rated in function of age, menopausal status, performance status and previous therapy. Toxicity (in case of 115 patients) was evaluated according to the WHO recommendation. The similar therapeutic effectiveness and less toxicity of the above drug combination compared to ADM + DBD regimen are demonstrated.

AB - The therapeutic efficacy of the combination of epirubicin + dibromodulcitol was evaluated in 108 previously treated or untreated patients with advanced breast cancer. The overall response rate was 39.8%, complete remission 3.7% (mean duration 6.3 months) and partial remission 36.1% (mean duration 3.5 months). The response was rated in function of age, menopausal status, performance status and previous therapy. Toxicity (in case of 115 patients) was evaluated according to the WHO recommendation. The similar therapeutic effectiveness and less toxicity of the above drug combination compared to ADM + DBD regimen are demonstrated.

UR - http://www.scopus.com/inward/record.url?scp=0023760355&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023760355&partnerID=8YFLogxK

M3 - Article

VL - 45

SP - 409

EP - 412

JO - Oncology

JF - Oncology

SN - 0030-2414

IS - 6

ER -